FDA Investigator Daniel W Cline

Daniel W Cline has conducted inspections on 17 sites in 4 countries as of 18 Nov 2002. See below for a list of the FDA enforcement documents resulting from those inspections.

Investigator Details

Number of Inspected Sites:
17
Last Inspection Date:
18 Nov 2002
Investigator Role:
FDA Investigator
Redica ID:
100009225
Countries of Inspections:
United States of America, Hungary, Italy, Croatia
FDA Investigators that have inspected at least one site in common with Daniel W Cline:
Alexander M Kay, Alexandra B Pitkin, Amalia C Himaya, Amir Alavi, Anderson, Angela Shepas, Anita Narula, PhD, Arsen Karapetyan, Azza Talaat, Barbara J Rincon, Barbara Jwilimczyk Macri, Barry Cherney, PhD, Bichsa T Tran, Binh T Nguyen, Bo Chi, PhD, Brien C Fox, Bryan A Galvez, Carla J Lundi, Carrie A Hughes, Caryn M Everly, Caryn M Mcnab, Charisse K Green, Charles D Boison, Cheron M Portee, Christina C Santos, Christina V Santos, Creighton T Tuzon, Davinna Ligons, PhD, Deborah A Greco, Devaughn Edwards, Diane Cvan Leeuwen, Doan T Nguyen, PharmD, Donna Ltartaglino Besone, Dr. Mark J Seaton, PhD, Esther C Broner, PhD, Frances Namuswe, PhD, Gene D Arcy, Haley H Seymour, Haroon Vohra (NMI), Hasan A Irier, PhD, Himanshu Gupta, PhD, Iris C Macinnes, James C Maclaughlin, James P Stumpff, James R Fleckenstein, Jee Chung, PhD, Jeffrey P Raimondi, Jennifer Gogley, Jennifer M Gogley, Jerome C Davis, Jocelyn E Massey, Jocelyn E Sparks, Joel Welch, PhD, Joey V Quitania, John L Stevens, John R Myung, Jose A Lopez, Juanita Banuelos, Junho Pak, Ka L Wong, Karen J Bak, Karen Takahashi, Katherine E Jacobitz, Kathleen B Swat, Kathleen R Jones, PhD, Kelvin Cheung, Kelvin X Sanders, Kendra A Biddick, Kim Lthomas Cruse, Kristy A Zielny, Laura Fontan, MS, Laurissa S Flowers, Leonard H Lavi, Liatte Kreuger, PharmD, Linda F Murphy, Linda Thai, Luis A Dasta, Marcia B Williams, Marcus F Yambot, Mariza M Jafary, Mary Ewilkerson Brinsko, Matthew B Casale, Maxyne T Lam, Michelle A Marsh, Michelle J Hines, Miguel A Martinez Perez, Mihaly S Ligmond, Minh D Phan, Mohsen Rajabi Abhari, FDA, Mra Greenc, Mra Mcculloughj, Nancy E Byerly, Nicholas L Hunt, Nicholas Obiri, PhD, Nicola M Fenty Stewart, Omotunde O Osunsanmi, Paquita F Segarra, Parul M Patel, Patrick C Klotzbuecher, Peter S Diak, Raymond W Brullo, Rebecca Rodriguez, Richmond K Yip, Robert D Tollefsen, Robert Darius, Robert S Sweeton, Roger F Zabinski, Rona Leblanc, PhD, Ronald L Koller, Ronda Leblanc, Sarah Arden, Scott R Nichols, PhD, Selene T Torres, Sidney B Priesmeyer, Sonia R Peterson, Stanley Au, Stephanie Mangigian, MS/OSH, RN, Steven Fong, MS, PhD, Susan F Laska, MS, Taichun Qin, PhD, Tamika White, Tania Y Hall, Terri L Dodds, Thao T Kwan, Thao X Tran, Theresa Kirkham (NMI), Thomas J Arista, Timothy P Lafave, Timothy T Kapsala, Tonia L Sawyer, Truong Xuan Nguyen (Andy), Uttaniti Limchumroon (Tom), Vashti E Bocker, Vickie L Anderson, Vien Q Le, Vilmary Negron Rodriguez, Viviana Matta, William J Leonard, William S Vitale, Yumi J Hiramine, Yvonne C Wilkes

Daniel W Cline's Documents

Publish Date Document Type Title
April, 2002 FDA 483 Archimica S.p.A. - Form 483, 2002-04-08
January, 2001 FDA 483 Curia Italy S.r.l. - Form 483, 2001-01-17
April, 2002 FDA 483 Response Archimica S.p.A. - Form 483R, 2002-05-16
February, 2000 FDA 483 Response Pacific Coast Tissue Bank - Form 483R, 2000-02-20
August, 2002 EIR Xellia Pharmaceuticals Ltd. - EIR, 2002-09-13
January, 2001 EIR Curia Italy S.r.l. - EIR, 2001-02-28
August, 2002 FDA 483 Response Pliva Hrvatska d.o.o. - Form 483R, 2002-10-28
August, 2002 EIR Pliva Hrvatska d.o.o. - EIR, 2002-09-13
February, 2000 FDA 483 Pacific Coast Tissue Bank - Form 483, 2000-02-02
August, 2002 FDA 483 Response Xellia Pharmaceuticals Ltd. - Form 483R, 2002-09-13
August, 2002 FDA 483 Xellia Pharmaceuticals Ltd. - Form 483, 2002-08-24
June, 2000 FDA 483 CALIFORNIA TRANSPLANT SERVICES, INC. - Form 483, 2000-06-23
June, 2000 EIR California Transplant Services Inc - EIR, 2000-06-23
August, 2002 FDA 483 Pliva Hrvatska d.o.o. - Form 483, 2002-08-30
November, 2002 EIR Allergan Sales, LLC - EIR, 2013-07-26
March, 2000 EIR IsoTis OrthoBiologics, Inc. - EIR, 2000-03-20
October, 2001 EIR Amgen, Inc - EIR, 2001-10-26
April, 2002 EIR Archimica S.p.A. - EIR, 2022-05-03

Experience Redica Systems’ NEW investigator profiles and dashboards

Redica Systems customers get access to over 1,400 FDA Investigator profiles, containing powerful analysis like:

  • Total inspections conducted
  • 483 rate
  • OAI rate
  • Warning Letter rate
  • Inspections by Industry, Scope, and Inspection Reason
  • And much more

Investigator Profiles are not sold as on-demand documents. If you’d like to see one, fill out the form below to connect with our Sales Team and get it in your inbox as little as 24 hours.

FDA Investigator Profile Icon

Talk to sales to access our investigator profiles

Loading...

Investigator Profiles Are Just the Tip of the Iceberg

Becoming a Redica Systems customer not only provides you with unlimited access to profiles similar to the one above for every current and former FDA Investigator, but also grants you access to:

Inspection Intelligence

  • Pre-Approval Inspection (PAI) trends
  • The ability to filter nearly any FDA enforcement action by GxP labels like GMP, GCP, etc.
  • Latest 483s: see what the trends are across all FDA Investigators
  • CFR Heatmap: Citations aggregated by Subpart by Year

Vendor Intelligence

  • Full inspection histories for your vendors down to the specific site level
  • All of the functionality mentioned above but isolated to just your vendors

Regulatory Intelligence

  • Zero in on the trends for a specific agency/regulator (ex. FDA, MHRA, EMA, Health Canada)
  • All the latest "Signals" from agencies around the world, segmented by Country, Type (ex. Guidance, Decree...), Category (ex. Rules/Regulations/Guidance, News, Reports...), Theme (ex. Cell and Gene Therapy, AI...), and more